| United States. Congress. Senate. Committee on Labor and Human Resources - 1993 - 362 Seiten
...in the capital markets to attract financing. The Office of Technology Assessment ("OTA") explained, Pharmaceutical R&D is an investment, and the principal...careful consideration of the effects on R&D is needed." It is fair to ask why pension funds, institutions and other investors would assume more risk by investing... | |
| United States. Congress. Senate. Committee on Labor and Human Resources - 1993 - 364 Seiten
...in the capital markets to attract financing. The Office of Technology Assessment ("OTA") explained, Pharmaceutical R&D is an investment, and the principal...changes, careful consideration of the effects on R&D is needed.1 It is fair to ask why pension funds, institutions and other investors would assume more risk... | |
| United States. Congress. House. Committee on Ways and Means. Subcommittee on Health - 1993 - 420 Seiten
...development." •Pharmaceutical R6D Is a risky investment,' the OTA stated In Its February 1993 report. "Therefore, high financial returns are necessary to...Induce companies to Invest In researching new chemical entitles." The OTA study focuses In large part on drugs approved by FDA In the early 1960s, and on... | |
| 1993 - 380 Seiten
...health of Americans, for health care costs, and for the future of the US pharmaceutical industry. OTA's report focuses mainly on the economic side of the...careful consideration of the effects on R&D is needed. The specific request for this study came from the House Committee on Energy and Commerce and its Subcommittee... | |
| United States. Congress. Senate. Committee on Labor and Human Resources - 1993 - 358 Seiten
...investment, and the principal characteristic of an investment is that money is spent today in the hopes or generating even more money in the future. Pharmaceutical...changes, careful consideration of the effects on R&D is needed.8 It is fair to ask why pension funds, institutions and other investors would assume more risk... | |
| United States. Congress. House. Committee on Ways and Means. Subcommittee on Health - 1993 - 428 Seiten
...development." •Pharmaceutical R&D is a risky investment,* the OTA stated in its February 1993 report. "Therefore, high financial returns are necessary to...companies to invest in researching new chemical entities." The OTA study focuses in large part on drugs approved by FDA in the early 1960s, and on market conditions... | |
| |